The CAPITA study of protein-conjugate pneumococcal vaccine and its implications for use in adults in developed countries.
Until 1990, Hemophilus influenzae type b (HITB) was a major cause of morbidity and mortality in toddlers and young children. A vaccine consisting of purified polyribosyl ribitol phosphate (PRP), the capsular polysaccharide (CPS) of HITB, had been shown to be ineffective as an antigen in the population at risk, and this vaccine was withdrawn from the market within a few years of its introduction. By contrast, the discovery that PRP, when covalently bound to an antigenic protein, stimulated antibody production in infants and toddlers, (1) led to the development of a vaccine that has all but eradicated HITB infection and brought about a near-disappearance of this organism in the United States.
From the Medical Service (Infectious Disease Section); Michael E. DeBakey Veterans Affairs Medical Center; Houston, TX USA; Department of Medicine; Baylor College of Medicine; Houston, TX USA; Department of Molecular Virology and Microbiology; Baylor College of Medicine; Houston, TX USA.
Daniel M
DM
Musher
From the Medical Service (Infectious Disease Section); Michael E. DeBakey Veterans Affairs Medical Center; Houston, TX USA; Department of Medicine; Baylor College of Medicine; Houston, TX USA; Department of Molecular Virology and Microbiology; Baylor College of Medicine; Houston, TX USA.
Maria C
MC
Rodriguez-Barradas
D000328:Adult; D019049:Developed Countries; D006192:Haemophilus Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000276:immunology; D019741:Haemophilus influenzae type b / Q000187:drug effects / Q000276:immunology; D006801:Humans; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011018:Pneumonia, Pneumococcal / Q000276:immunology* / Q000517:prevention & control*; D011134:Polysaccharides / Q000008:administration & dosage / Q000276:immunology; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology*
C538862:13-valent pneumococcal vaccine; D018073:Haemophilus Vaccines; D022242:Pneumococcal Vaccines; D011134:Polysaccharides; D018074:Vaccines, Conjugate; C008984:polyribitol phosphate
CAPITA; Pneumococcus; conjugate vaccine; pneumonia; vaccine